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Abstract 
Background and Purpose My purpose was to obtain a reliable treatment score for unruptured 
intracranial aneurysms (UIAs) from variables known at baseline. 
Methods The series included 142 patients with UIAs diagnosed between 1956 and 1978, when UIAs 
were not treated and were followed up until the first aneurysm rupture, death or the last contact. 
Previously published unruptured intracranial aneurysm treatment scores (UIATS) were recorded and 
finally was a new treatment score was constructed. 
Results The median follow-up time was 21.0 years (IQR10.4-31.8 years). A total of 34 patients had an 
aneurysm rupture during 3064 person-years of follow-up. The UIATS differed slightly between those 
with and without an aneurysm rupture (9.4+2.8 vs. 8.3+3.1,p=0.082). The receiver operating 
characteristics curve of the UIATS for predicting rupture showed a modest area under the curve (AUC) 
(0.602, 95% CI 0.495-0.709, p=0.074). The best new treatment score consisted of 4 variables: age <40 
years (2 points), current smoking (2 points), UIA size >7 mm (3 points) and location (anterior 
communicating artery, 5 points; internal carotid bifurcation, 4 points, and posterior communicating 
artery, 2 points). Scores of 5–12 points were associated with high cumulative UIA rupture rates (16%–
60% at 10 years and 49%–80% at 30 years), favoring UIA treatment. Scores of 1–4 points (3% at 10 
years and 18% at 30 years) favored conservative treatment and needed additional indications for 
treatment. Patients with a score of 0 points should not be treated (no ruptures during 513 follow-up 
years). The AUC for this scoring was 0.755 (95%CI 0.657–0.853, p<0.001) and was better than that of 
the UIATS (p=0.02). 
Conclusions This new simple and rapid scoring system is quite reliable for evaluating treatment 
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Subarachnoid hemorrhage (SAH) is a serious disease,1-4 but its incidence is gradually decreasing5,6 
and the mean age of patients is increasing.2,6 The decrease in incidence predominantly in the younger age 
groups is probably due to a reduction in cigarette smoking in the general population, and perhaps also to 
more precise SAH diagnoses.5,6 
To prevent SAH occlusion of unruptured intracranial aneurysms (UIAs) has been performed for the 
last 40 years.4,7,8 At the same time, the increasing use of MRI for examining symptoms unrelated to UIAs 
(chronic headache, dizziness, vascular diseases, dementia, etc.) has led to the detection of more 
asymptomatic UIAs than previously.4,7,8 Since the prevalence of aneurysms is not decreasing,9 probably 
their lower rupture risk has resulted in lower SAH incidence rates. The decrease in SAH incidence 
combined with the increase in the discovery of UIAs has made interpretation of the indications for 
treating UIAs more difficult. 
The indications for UIA treatment were in any case already challenging because of a lack of 
factually based prospective natural history studies. This was due to differences in the selection of UIA 
patients for conservative follow-up, majority of whom were considered to have a low risk of rupture, 
while some had a shorter life expectancy or higher treatment risks.10 True new natural history studies of 
UIAs are impossible nowadays without treatment selection bias. An unruptured intracranial aneurysm 
treatment score (UIATS) based on the opinions of 69 worldwide experts has been published recently,8 but 
unfortunately it was relatively complex, did not include patient data and lacked validation. 
There is, however, one almost lifelong prospective follow-up study of UIAs among patients of 
working age1,11-13 which was not subject to treatment selection bias and was considered to be of the 
highest quality and to have the least sources of bias of all known UIA studies.10,14 This also investigated 
the validity of its UIATS and searched for a new treatment score from variables known at baseline which 
could better predict the lifelong rupture rate. 
 
METHODS 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 




This study included 142 European white patients (median age 42, range 15–61 years; 76 women) 
with 182 UIAs diagnosed at the Department of Neurosurgery, Helsinki University Central Hospital, 
between 1956 and 1978, when UIAs were not operated on in Finland. This hospital was responsible for 
neurosurgical services for almost the whole Finnish population at that time.12,15 For details of the cohort 
and the examinations performed, see the previous follow-up reports.1,10-13,15 Approval for the surveys and 
the collecting of follow-up data had been obtained from the local ethics committee in compliance with 
national legislation and the Declaration of Helsinki. 
Of the 142 patients with UIAs, 131 had a prior SAH with multiple aneurysms at baseline. Only the 
verified ruptured aneurysm was operated on, and occlusion of the aneurysm without sacrifice of the 
parent vessel was confirmed by postoperative angiography. 
 
Follow-up methods 
Detailed follow-up protocols have been reported previously.1,10-13,15-19 Briefly, the follow-up of the 
patients was based on outpatient clinic visits, postal questionnaires and telephone interviews obtained 
from patients and/or proxies every 10 years from the early 1960’s onwards. The structured questionnaire 
included patient characteristics, previous diseases, hospital visits, medication and health behavior. The 
last patient follow-up was performed in 2012, when 20 patients were alive without rupture of the 
UIA.12,13,15,19 By the end of follow-up 113 (80%) had died and of them 86 of causes unrelated to UIAs.15 
Additional information on all the patients was obtained from medical records supplied by other 
hospitals and general practitioners, and the accuracy of the data with regard to diseases, medication, 
health behavior and blood pressure (BP) levels was verified. Autopsy reports and official death 
certificates were examined for all deceased patients. In Finland a statutory medico-legal autopsy is 
performed on all those who die due to trauma or unknown causes (Act on the Inquest into the Cause of 
Death, 459/1973, Finnish Law). The follow-up was complete. 
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Risk factors 
The UIATS7,8 variables for each patient were recorded using only those known at the baseline (Table 
1). Hypertension was defined as a systolic pressure repeatedly greater than 140 mm Hg, a diastolic 
pressure greater than 90 mm Hg, or use of antihypertensive medication.15,16 Current smoking was 
ascertained at baseline, and alcohol consumption was recorded in approximate grams of absolute ethanol 
consumed within one week (1 standard drink = 12 g of alcohol). A family history of SAH was defined as 
>2 first-degree relatives with verified ruptured aneurysms. 
 
Aneurysm measurements 
All angiographies performed at baseline were examined by a neuroradiologist who had no 
knowledge of the patients’ case histories.11,13,17 The maximum diameter (D) of the UIAs, together with 
their neck width (n), was measured from standard projections of 2D conventional angiograms at baseline 
and used to calculate the aspect ratio (D/n).13,19 The size ratio was not available. Also recorded were the 
location and shape of the UIA (round, oval, irregular or lobulate). Aneurysm growth rates and de novo 
aneurysm formation, which have been reported previously, were not used here since the time between 




The data were analyzed with IBM SPSS Statistics, version 24.0, for Windows (IBM Corp., Armonk, 
NY, USA). UIATS variables at baseline were compared by reference to future aneurysm rupture status 
using Fisher's exact test or the Pearson Chi-square test. Sum scores [expressed as mean + standard 
deviation (SD) and median with interquartile range (IQR)] were compared with t-tests and the Mann-
Whitney U- test. Sensitivity, specificity and positive and negative predictive values were calculated for 
the UIATS. 
Cox proportional hazards regression with a forward stepwise procedure (entry into the model if p 
<0.15) and Wald statistics was employed to estimate hazard ratios (HRs) and 95% confidence intervals 
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(CIs) to test the predictors of future aneurysm rupture. Each patient was followed up until SAH, death 
from a cause other than SAH, treatment of the UIA (3 cases with a follow-up lasting >24.4 years), or the 
last follow-up contact. The test of significance was based on changes in the log (partial) likelihood. The 
variables known at the beginning of the follow-up were sex, location of the largest UIA, and the UIATS 
variables. The proportionality assumption was confirmed. The grouping of the variables was the same as 
that of the UIATS. 
The new integer risk score points were based on the regression coefficients in the final Cox 
proportional hazards model, the areas under the curve (AUC) for the receiver operating curves (ROC) 
being calculated for both the UIATS and the new prognostic treatment scores. The C-statistic with 95% 
CIs was used to test how the total scores matched the observed rupture rates, the AUC between scores 
being analyzed using the technique of Hanley and McNeil.20 This statistical analysis was performed 
using MedCalc for Windows, version 18.9 (MedCalc Software, Ostend, Belgium). The cumulative 
probabilities of aneurysm rupture at 10 and 30 years after the diagnosis according to the new score 
groups was calculated by performing the Kaplan–Meier product-limit analysis. A two-tailed P value 




Patient characteristics and follow-up 
During a total follow-up of the 142 patients (median 21.0 years, range 0.8–52.3 years per patient) for 
3064 person-years 34 patients (24%) had an aneurysm rupture from an UIA (approximate annual 
incidence, 1.1%). The cumulative rate of SAH was 11% (95% CI, 5–16%) at 10 years and 30% (21–
39%) at 30 years. The median follow-up time between diagnosis and a subsequent aneurysm rupture was 
10.6 years (range 1.2–24.2 years), and that of patients without a rupture 24.4 years (range 0.8–52.3 
years). 
 
UIATS of patients 
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The UIATS factors of the patients, stratified by their later aneurysm rupture status, are shown in 
Table 1. UIATS was only slightly higher in those with a rupture than in those without (p=0.087). The 
UIATS favored UIA repair in 141 patients, giving a high sensitivity of UIATS in detecting cases with 
aneurysm rupture (100%) but very low specificity (1%). All patients were Finns and most had a prior 
SAH. If these were not taken into account UIATS was slightly higher in those with a later rupture 
(3.44+2.84 vs. 2.34+3.11, p=0.069). UIATS predicted UIA rupture relatively modestly: sensitivity 20/34 
(59%), specificity 58/108 (54%), positive predictive value 20/70 (28%), and negative predictive value 
58/72 (81%). 
Current smoking was missing from the data for 6 of the 34 patients with an aneurysm rupture (18%) 
and 13 of the 108 without a rupture (12%). The mean score per patient was 8.55+3.04 if patients without 
smoking information were excluded and the mean scores by later rupture status were 9.43+2.77(range 3–
13) vs. 8.29+3.08 (3–15) (p=0.082). 
 
Risk factors for UIA rupture and the new treatment score 
All the UIATS factors with additional UIA locations and sex were tested with Cox regression 
analysis to identify the variables which best predicted a future aneurysm rupture. Age <40 years, 
aneurysm diameter >7 mm, current smoking, UIA located either in the internal carotid bifurcation or in 
the anterior (ACOA) or posterior communicating arteries (PCOA) predicted a subsequent rupture (Table 
2). Although women had aneurysm ruptures more frequently than men (23 of the 76 women vs. 11 of the 
66 men), female sex was not an independent risk factor for aneurysm rupture (HR 1.54, 95% CI 0.64-
3.71, p=0.34). A new system for scoring UIA treatment was constructed from the regression coefficients 
of the 4 variables (Table 2). 
The AUC for the ROC of simple scoring (points 0 vs. 1 for 4 variables; sum score 1, Figure 1) was 
fair (AUC 0.730, SE 0.052, 95%CI 0.628-0.831, p<0.001), and that for the wider scoring curve (score 
sum range 0-12;sum score 2 in Figure 1) was somewhat better (0.755, SE 0.050, 95%CI 0.657-0.853, 
p<0.001), but that for the UIATS was no more than modest (0.618, SE 0.059, 95% CI 0.502-0.733, 
p=0.059). The inclusion of sex in the scoring (women vs. men, 2 vs. 0 points) did not improve the ROC 
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curve (sum score 3 range 0-14; 0.766, SE 0.049, 95%CI 0.669-0.863, p<0.001; Figure 1). The new scores 
did not differ significantly from one another but all these were better than UIATS (p<0.05). The optimal 
cut-off point was obtained with the sum score 2 at >5 vs. <5 points for sensitivity (0.607) and specificity 
(0.789) (Figure 1 and Table 3). 
The new scores differed with respect to future aneurysm rupture status. The sum score 1 with the use 
of 0 vs. 1 for each of the 4 predictors was higher (p<0.001) in those with a later rupture than in those 
without (2.18+0.86 vs. 1.35+0.92), as was the difference between the scores with the wider scoring (sum 
score 2, 5.32+2.36 vs. 3.04+2.23, p<0.001). 
Sum score 2 was grouped into 4 categories according to the long-term cumulative aneurysm rupture 
rates and predicted future aneurysm rupture (p<0.001) (Table 3, Figure 2). 18 patients with a treatment 
score of 0 seem not to need UIA occlusion treatment (annual incidence 0%, 95% CI 0-0.72%). 14 of 
these patients were non-smokers aged >40 years and had small (<7 mm) middle cerebral artery 
aneurysms. None of them had a rupture during 385 follow-up years (approximate annual incidence 0%, 
95% CI 0-0.96%).  
On the other hand, patients with scores in the range 5-12 should be treated, since their aneurysms 
have a high cumulative UIA rupture risk. Patients with scores 1-4 should be individually evaluated, 
taking into account other rupture and treatment-associated factors (experience and the results of 
treatment), life expectancy and also whether cessation of smoking can reduce the risk still further. 
If smoking is excluded from sum score 2 because of missing values in 19 cases, AUC decreased 
(0.708, SE 0.054, 95%CI 0.603-0.814, p<0.001) and the optimal cut-off point was at >4 vs. <4 points for 
sensitivity (0.529) and specificity (0.824). 
 
DISCUSSION 
The treatment score obtained from this prospective study with an almost lifelong follow-up and a 
very low treatment selection bias suggests that treatment of UIAs among patients of working age can be 
estimated quite reliably with only 4 variables at baseline. Patient age (< 40 years), cigarette smoking, 
aneurysm size (diameter > 7 mm), and location in the ACOA, PCOA or internal carotid bifurcation 
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determine the risk of UIA rupture significantly better than does the UIATS.  The small middle cerebral 
artery aneurysms (<7 mm) in non-smokers aged >40 years seem to have so low a rupture risk that they 
can be treated conservatively. 
Simultaneously with the discovery of increasing numbers of UIAs, it is likely that the indications for 
treatment will decrease, because of the decline in the prevalence of smoking and the incidence of SAH,6 
and because of the discovery of incidental UIAs in older people than previously. These patients are also 
less likely to be smokers or to have higher treatment risks because of age.21 Existing aneurysms are also 
less likely to rupture in the future if smoking decreases further.12,19 The cost-effectiveness ratio of UIA 
treatment is thus increasing. Treatment scores have not previously been calculated from patient-based 
data to prevent life-time aneurysm rupture risk. 
Since the results of the various studies of risk factors affecting UIA rupture and growth differ an 
attempt was made to improve the reliability of treatment recommendations by means of a UIATS.7,8 The 
study concerned did not include patient data, however, but was based on the opinions of 69 worldwide 
aneurysm treatment experts. The UIATS included several variables but was lacking in any validation. 
The present study shows that UIATS overestimates the treatment indications of patients of working age 
and that its specificity for the lifelong occurrence of UIA rupture is low and its predictive value in terms 
of ROC was modest. Most of the present patients obtained 6 UIATS points, only because of their prior 
SAH history and Finnish nationality. The UIATS recommended UIA treatment for 99% of the patients, 
but 24% had an aneurysm rupture. The UIATS score specificity seemed to be markedly reduced by these 
two variables. 
The UIATS reflects treatment policy in recent decades, during which time the proportion of treated 
UIAs increased10,21,22  simultaneously with the discovery of UIAs and the introduction of endovascular 
treatment for older patients as well and for those with increased treatment risks. The cost-effectiveness 
ratio will probably also have increased over that period since more and more UIAs which would never 
have ruptured were being treated, but the mortality rates associated with the treatment, 1-2%, and the 
morbidity of approximately 10% remained constant.21 The overestimation of UIA treatment associated 
with the UIATS may also have been due to patients’ fears of a possible aneurysm rupture and in part also 
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to conflicts of interest, enthusiasm, or perhaps economic considerations, since the consultants involved 
were treating UIAs as part of their gainful employment. A similar overtreatment in real-world practice 
with a low AUC value was seen when UIATS was coded for patients with UIA treatment.23 Thus there 
was a clear need a treatment scoring system based on patient data with reliably measurable variables at 
baseline. 
The present results show that even though small UIAs in patients of working age can rupture during 
the remaining life time, the majority of these do not. These patients are usually healthy, without any 
chronic diseases and without any evident contraindications for treatment. Life expectancy is shortened of 
principally among patients with UIAs who are aged < 40 years at baseline and who have a later aneurysm 
rupture.15,19 Such patients usually show clear indications for treatment irrespective of the size of the 
aneurysm, particularly if they smoke, since the cumulative rupture risks at 10 and 30 years are quite high. 
Long-term smoking increases the risk for UIA growth, which in turn can result in rupture.19 In addition, 
if the UIA is located in the ACOA, PCOA or internal carotid bifurcation the indication for treatment will 
be even higher.10,12,21,22 Although ACOA and PCOA aneurysms are known to carry a higher rupture risk 
than other aneurysms, the risk may be even higher than has previously been shown because these UIAs 
have more frequently been treated at baseline than have posterior circulation UIAs, for example.10,21,22 
Posterior circulation UIAs may also have higher rupture risk, which may possibly have been obscured in 
the present series because of the small number of such cases. On the other hand, a significantly higher 
rupture risk was seen here in internal carotid bifurcation UIAs, an aneurysm location that is known to be 
more frequent in young adults and is associated with a higher growth rate.19 
The present treatment score predicted long-term UIA ruptures better than did any of the separate 
factors alone, so that those with a score of at least 5 points had a mean cumulative rupture risk of 50% at 
30 years. This favors treatment if the risk cannot be reduced, e.g. by cessation of smoking. Indeed, the 
latter may even be a treatment option if the score can be reduced to a level which favors conservative 
treatment.24-27 Women are known to have a higher incidence of SAH than men, partly because they have 
a longer life expectancy and a higher prevalence of aneurysms (approximately 1.6-fold).9,28 It is also 
known that, despite their lower prevalence of smoking, women also have a higher aneurysm growth rate 
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than men,11,14,19 but even so, the addition of female sex to the predictive factors did not improve the score 
in the present study. 
The strengths of this study lie in the complete and almost lifelong follow-up and the very limited 
treatment selection bias.12,27 Correspondingly, this cohort was considered previously to be of high quality 
for research purposes and to have low sources of bias relative to those used in other UIA studies.10,14 
Finnish people have been considered to be subject to a higher risk of aneurysm rupture,10 but the Finnish 
cohort has proved to be the only one in the PHASES score study that represented a true natural history of 
the condition. The incidence of SAH is no higher in Finland than elsewhere when standardized for the 
study design with its inclusion and exclusion criteria, the accuracy of diagnosis and the sex and age 
distributions of the population.6 The Nordic countries seem to have similar incidences of SAH. 
One limitation of the study is the relatively small sample size despite a long total follow-up time as 
compared with prospective multicenter study populations, which have on the other hand had shorter 
follow-ups and high treatment selection bias. Patients with a prior history of SAH have not been shown 
to have a significantly higher risk of aneurysm rupture than others when confounding factors are taken 
into account.10 Additional controlling for smoking would have reduced the possible association between 
prior SAH and the risk of UIA rupture, since smoking affects both aneurysm rupturing and the 
occurrence of multiple aneurysms. Only one smaller prospective Japanese study has suggested that prior 
SAH might increase the risk of SAH, but in that instance smoking was not taken into account.10 Our 
patients were also younger than those in the other studies. Patients of working age are usually treated 
nowadays, which has led to biased results with regard to the natural history of UIAs. Elderly patients 
with small UIAs are more likely to be left untreated, because of the low UIA rupture rate. Also, these 
results should not be used explicitly for recommending the treatment of small (<7 mm) ACOA 
aneurysms in non-smoking 70-80-year-old female patients, even when the score sum is 5. 
In conclusion, this new simple and rapid scoring system is better than UIATS for evaluating 
treatment indications and achieving lifelong prevention of UIA ruptures. The findings suggest that UIAs 
in patients of working age can be treated with a better focus and improved cost-effectiveness provided 
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that this is undertaken by experienced physicians achieving good treatment results. This scoring system 
still requires validation in a new cohort of patients. 
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Figure 1. Receiver operating characteristic (ROC) curves for predicting the long-term rupture risk 
of unruptured intracranial aneurysms. 
All the new scores predicted long-term aneurysm rupture better (p<0.05) than the previously used 
unruptured intracranial aneurysm treatment score (UIATS). See text for detailed calculations of the areas 
under the receiver operating characteristic curves. 
 
Figure 2. Long-term cumulative aneurysm rupture risk of treatment score (sum score 2). 
A score > 5 points favors aneurysm treatment, while aneurysms with scores of 0 points are better treated 
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Table1. Unruptured intracranial aneurysm treatment scores (UIATS) stratified by aneurysm 
rupture status 










Age (single)(%)* < 40 years / 4 20 (34) 38 (66) 58 (100) 
40-60 years / 3 14 (17) 70 (83) 84 (100) 
61-70 years / 2 0 0 0 
71-80 years / 1 0 0 0 
>80 years / 0 0 0 0 
Risk factor incidence 
(multiple)(%) 
Previous SAH from a 
different aneurysm /4  
31 (24) 100 (76) 131 (100) 
Familial intracranial 
aneurysms or SAH / 3 
3 (33) 6 (67) 9 (100) 
Finnish ethnicity / 2 34  (24) 108 (76) 142 (100) 
Current cigarette smoking / 3 20 (29) 50 (71) 70 (100) 
Hypertension / 2 13(27) 36 (73) 49 (100) 
Autosomal-polycystic kidney 
disease / 2 
1 (50) 1 (50) 2 (100) 
Current drug abuse / 2 0 0 0 
Current alcohol abuse /1 5 (24) 16 (76) 21 (100) 
Clinical symptoms 
related to UIA 
(multiple)(%) 
Cranial nerve deficit /4 3 (60) 2 (40) 5 (100) 
Clinical or radiological mass 
effect /4 
1 (25) 3 (75) 4 (100) 
Thromboembolic event from 
the aneurysm /3 
0 1 (100) 1 (100) 
Epilepsy 0 0 0 
Other (multiple)(%) Reduced quality of life due to 
fear of rupture /2 
0 0 0 
Aneurysm multiplicity /1 7 (21) 26 (79) 33 (100) 
Maximum diameter 
(single)(%) 
<4.0 mm / 0 15 (29) 36 (71) 51 (100) 
4.0-6.9 mm / 1 9 (14) 56 (86) 65 (100) 
7.0-12.9 mm / 2 8 (38) 13 (62) 21 (100) 
13.0-24.9 mm / 3 1 (33) 2 (67) 3 (100) 
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>24.9 mm / 4 1 (50) 1 (50) 2 (100) 
Morphology 
(multiple)(%) 
Irregularity or lobulation / 3 3 (14) 19 (86) 22 (100) 
Aspect ratio >1.6 or size ratio 
>3 / 1 
14 (22) 51 (78) 65 (100) 
Location (single)(%) BasA bifurcation / 5 0 2 (100) 2 (100) 
Vertebral/basilar artery / 4 0 2 (100) 2 (100) 
AcomA/pcomA / 2 14 (34) 27 (66) 41 (100) 
MCA / 0 15 (23) 49 (77) 64 (100) 
Life expectancy due 
to chronic and/or 
malignant diseases 
(single)(%) 
<5 years / -4 0 2 (100) 2 (100) 
5-10years / -3 0 4 (100) 4 (100) 
>10 years / -1 0 7 (100) 7 (100) 
Co-morbid disease 
(multiple)(%) 
Neurocognitive disorder / -3  0 1 (100) 1 (100) 
Psychiatric disease or 
coagulopathy / -2 
0 3 (100) 3 (100) 
Age-related risk 
(single)(%)* 
< 40 years / 0 20 (34) 38 (66) 58 (100) 




<6.0 mm / 0 22 (21) 85 (79) 107 (100) 
6.0-10.0 mm / -1 9 (32) 19 (68) 28 (100) 
10.1-20.0 mm / -3 2 (40) 3 (60) 5 (100) 




High / -3 3 (50) 3 (50) 6 (100) 
Low/ 0 31 (23) 105 (77) 136 (100) 
Intervention-related 
risk 
Constant / -5 34 108 142 
UIATS Mean (SD) 9.09(2.83) 8.05(3.14) 8.30(3.09) 
 Median (IQR) 9 (7-12) 8 (5-10) 8 (6-11) 
 Total score sum/no. patients 309/34 869/108 1178/142 
UIATS score 
recommendation 
Favors UIA repair (%) 34 (24) 107 (76) 141 (100) 





Favors UIA repair (%) 33 (26) 95 (74) 128 (100) 
“not definitive”(%) 1 (8) 12 (92) 13 (100) 
Favors conservative 
management (%) 
0 1 (100) 1 (100) 
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UIA = unruptured intracranial aneurysm; SAH = subarachnoid hemorrhage; AcomA = anterior 
communicating artery; A2 = pericallosal artery; BasA = basilar artery; MCA= middle cerebral 
artery; IQR = interquartile range (range between 25th and 75th percentiles); pcomA = posterior 
communicating artery; SAH = subarachoid hemorrhage; UIATS score = unruptured intracranial 
aneurysm treatment score. 
UIATS vs. SAH in all the patients: sensitivity = 100%, specificity = 1%, positive predictive value = 
24%, negative predictive value = 100%. 
UIATS vs. SAH in all patients without Finnish ethnicity: sensitivity = 97%, specificity = 12%, 
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Hazard ratio (95% 
CI) 
Age at diagnosis <40 
years)  
0.649 0.349 1.91 (0.97-3.79) 0.778 0.442 2.18 (0.92-5.18) 2 
Current smoking at 
baseline 
0.913 0.420 2.49 (1.10-5.67)† 0.682 0.454 1.98 (0.81-4.81) 2 
Maximum diameter 
of unruptured 
aneurysm (>7 mm) 
0.811 0.378 2.25 (1.07-4.72)† 1.125 0.422 3.08 (1.35-7.04)‡ 3 




0.928 0.533 2.53 (0.89-7.18)  1.622 0.589 5.06 (1.59-16.07)‡ 5 
Internal carotid 
bifurcation 




0.429 0.377 1.54 (0.73-3.21) 0.741 0.476 2.10 (0.83-5.33) 2 
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Of the 33 patients with posterior communicating artery aneurysms, 10 (30%) suffered a rupture, as did 4 of 8 (50%) anterior communicating and 3 of 8 
(38%) internal bifurcation carotid artery aneurysms. 
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Table 3. Risk sum score and cumulative incidence of aneurysm rupture 
 
 
The annual rupture rate is calculated by dividing number of patients with an aneurysm rupture by the 
person-years of follow-up, shown in parentheses. CI indicates confidence intervals. 
 
Use of 5-12 points as a recommendation for aneurysm treatment gives a sensitivity 61%, specificity 79%, 
positive predictive value 46% and negative predictive value 87%. 
 










risk score points* 
No. of patients (%) Annual rupture rate (%) 
Cumulative rupture rates, % (95% CI) 
10 years 30 years 
0 18 0 (0/513) 0 0 
1-4 68 0.6 (11/1722) 3 (0-8) 18 (8-28) 
5-8 32 2.2 (13/594) 16 (3-29) 49 (29-70) 
9-12 5 6.8 (4/59) 60 (17-100) 80 (44-100) 
Total 123 1.0 (28/2888) 11 (5-16) 30 (21-39) 
